RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$45.77
−3.95%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.21
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.19
- EPS estimate
- -$1.12
- Revenue actual
- —
- Revenue estimate
- $2.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +4.0%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $61
- PT range
- $52 – $66
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026